OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates	489
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses	269
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action	237
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2	192
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic	170
Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases	144
Malaria vaccines since 2000: progress, priorities, products	143
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19	111
Protein-based antigen presentation platforms for nanoparticle vaccines	107
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents	104
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19	101
Access to and equitable distribution of COVID-19 vaccine in low-income countries	92
COVID-19 vaccines: breaking record times to first-in-human trials	82
The use of viral vectors in vaccine development	77
Extended interval BNT162b2 vaccination enhances peak antibody generation	75
Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation	74
Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel	67
Vaccines for human fungal diseases: close but still a long way to go	66
Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees	65
Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines	60
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models	60
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy	60
Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein	54
Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice	50
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate	46

Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens	46
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza	46
A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection	46
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets	45
A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus	45
Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis	45
Design of a broadly reactive Lyme disease vaccine	44
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge	44
Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination	44
SARS-CoV-2 structural features may explain limited neutralizing-antibody responses	43
Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection	43
Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters	42
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates	42
Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations	40
Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge	39
Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters	39